EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII



Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII



American Journal of Hematology 45(2): 142-145



Hemorrhage in a patient with factor VIII inhibitor is associated with increased morbidity and mortality. Treatment with factor IX complex concentrates or recombinant factor VIIa (rVIIa) may not control bleeding and may induce thrombosis. In this study, continuous infusion of a monoclonal antibody-purified factor VIII [correction of factor VII] concentrate (Monoclate-P) was used successfully in two hemophilic patients with factor VIII alloantibodies and one nonhemophilic patient with a factor VIII autoantibody. In two patients, hemorrhage was life-threatening, and, in one, bleeding did not stop with repeated infusions of activated factor IX complex concentrates. The patients' ages ranged from 4 to 15 years, and the inhibitor levels from 6 to 300 Bethesda units/ml. Clinical hemostasis was excellent, and in vivo recovery of infused factor VIII was achieved. When an excess of monoclonal factor VIII was added to the inhibitor plasma in vitro, a stable level of residual factor VIII activity was noted after an initial rapid loss. This second-order reaction occurs in plasmas of patients with type I factor VIII inhibitors. In one patient, we showed that the saturation dose of the factor VIII inhibitor predicted in vivo recovery of factor VIII:C. These data emphasize the importance of characterizing the kinetic reactions of the factor VIII inhibitor. Furthermore, we confirm previous reports that continuous infusion of monoclonal factor VIII is a safe and effective treatment of patients with factor VIII inhibitors in whom hemorrhage is either life-threatening or refractory to standard treatment.

Accession: 008381557

Download citation: RISBibTeXText

PMID: 8141119

DOI: 10.1002/ajh.2830450209

Download PDF Full Text: Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII



Related references

Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII. American Journal of Pediatric Hematology/Oncology 15(1): 107-110, 1993

Continuous infusion of monoclonal antibody-purified factor VIII. American Journal of Hematology 36(3): 211-212, 1991

Immune tolerance induction by continuous infusion of monoclonal antibody-purified factor VIII in children. Blood 82(10 SUPPL 1): 62A, 1993

Home therapy from minor surgery and major bleeding using continuous infusion of monoclonal antibody purified factor VIII concentrate. Blood 86(10 SUPPL 1): 352A, 1995

Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. Journal of Clinical Investigation 82(1): 123-128, 1988

Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII. Lancet 337(8751): 1222-1222, 1991

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia 11(2): 84-91, 2005

Oral administration of factor VIII contributes to the prevention of anti-factor VIII antibody development after protein infusion, and prolongs factor VIII transgene expression post-adenoviral gene transfer. Blood 102(11): 163a, November 16, 2003

A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells. British Journal of Haematology 81(4): 533-538, 1992

A murine monoclonal anti-factor VIII inhibitory antibody and two human factor VIII inhibitors bind to different areas within a twenty amino acid segment of the acidic region of factor VIII heavy chain. Blood Coagulation & Fibrinolysis 1(1): 9-15, 1990

Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 8(5): 629-634, 2002

Continuous infusion porcine factor VIII in the treatment of patients with factor VIII antibodies. Blood 84(10 SUPPL 1): 196A, 1994